Taniguchi K, Tabata M, Iida T, Hori T, Yagi S, Uemoto S
First Department of Surgery, Mie University School of Medicine, 2-174, Edobashi, Tsu City, Mie Prefecture 514-8507, Japan.
Eur J Surg Oncol. 2006 Mar;32(2):208-12. doi: 10.1016/j.ejso.2005.11.006. Epub 2005 Dec 27.
To examine micrometastasis in node-negative hilar bile duct carcinoma (HBDC) using an immunohistochemical method and evaluated the clinical significance.
Four hundred and twenty three regional lymph nodes from 28 patients with node-negative HBDC who had undergone a resection were immunostained with an antibody against cytokeratins eight and 18 (CAM 5.2).
Lymph node micrometastasis was detected in 11 of the 28 patients and 14 of the 423 lymph nodes. Lymph node micrometastasis was significantly correlated with the pT classification (p=0.03), the histopathological grading (p=0.01) and venous invasion (p=0.05). The 5-year survival rate of the patients with lymph node micrometastasis was 21.8%, as opposed to 66.5% in the patients without micrometastasis. Patients with micrometastasis showed a significantly poorer survival rate than those without micrometastasis (p=0.02).
The results suggest that immunohistochemically detected lymph node micrometastasis has an impact on the outcome in HBDC.
采用免疫组化方法检测淋巴结阴性的肝门部胆管癌（HBDC）中的微转移，并评估其临床意义。
对28例行手术切除的淋巴结阴性HBDC患者的423个区域淋巴结进行细胞角蛋白8和18抗体（CAM 5.2）免疫染色。
28例患者中有11例检测到淋巴结微转移，423个淋巴结中有14个检测到微转移。淋巴结微转移与pT分类（p = 0.03）、组织病理学分级（p = 0.01）和静脉侵犯（p = 0.05）显著相关。有淋巴结微转移患者的5年生存率为21.8%，无微转移患者为66.5%。有微转移的患者生存率明显低于无微转移的患者（p = 0.02）。
结果表明，免疫组化检测到的淋巴结微转移对HBDC的预后有影响。
Zotero 插件